Replies to post #440 on Vaxart Inc (VXRT)

[RAND]

4:42am est 1/12/18 Aviragen Therapeutics Board recommends that stockholders vote FOR the proposed merger with Vaxart
Briefing.com
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today reiterated its support of the pending merger with Vaxart, Inc., which was unanimously approved by the Aviragen Board of Directors. In reiterating its support for and recommending that Aviragen stockholders vote in favor of the proposed merger with Vaxart at the special meeting of stockholders on February 6, 2018, the Company notes that: The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart's estimated potential valuation prior to the merger is approximately $158 million. Aviragen stockholders will have the opportunity to participate in the significant upside potential of the mergerAviragen's Board conducted a thorough process that included an extensive review of strategic alternatives